Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/ijms241210199
Keywords
antiangiogenic; cancer; dopamine (DA); dopamine agonists (DA-Ag); endometriosis; osteoarthritis (OA); vascular endothelial growth factor (VEGF); vascular endothelial growth factor receptor (VEGFR)
Ask authors/readers for more resources
Dopamine and dopamine agonists have the potential to inhibit angiogenesis through the VEGF pathway. They can prevent important processes such as proliferation and migration by blocking the functions of VEGF and VEGFR2 through the D2 receptor. However, more research is needed to fully understand their mechanism and efficacy in diseases like cancer, endometriosis, and OA. This review aims to describe the antiangiogenic action of the DA-D2R/VEGF-VEGFR2 system and compile relevant findings from experimental studies and clinical trials.
Dopamine (DA) and dopamine agonists (DA-Ag) have shown antiangiogenic potential through the vascular endothelial growth factor (VEGF) pathway. They inhibit VEGF and VEGF receptor 2 (VEGFR 2) functions through the dopamine receptor D2 (D2R), preventing important angiogenesis-related processes such as proliferation, migration, and vascular permeability. However, few studies have demonstrated the antiangiogenic mechanism and efficacy of DA and DA-Ag in diseases such as cancer, endometriosis, and osteoarthritis (OA). Therefore, the objective of this review was to describe the mechanisms of the antiangiogenic action of the DA-D2R/VEGF-VEGFR 2 system and to compile related findings from experimental studies and clinical trials on cancer, endometriosis, and OA. Advanced searches were performed in PubMed, Web of Science, SciFinder, ProQuest, EBSCO, Scopus, Science Direct, Google Scholar, PubChem, NCBI Bookshelf, DrugBank, livertox, and Clinical Trials. Articles explaining the antiangiogenic effect of DA and DA-Ag in research articles, meta-analyses, books, reviews, databases, and clinical trials were considered. DA and DA-Ag have an antiangiogenic effect that could reinforce the treatment of diseases that do not yet have a fully curative treatment, such as cancer, endometriosis, and OA. In addition, DA and DA-Ag could present advantages over other angiogenic inhibitors, such as monoclonal antibodies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available